Sun Yat-sen University
Clinical trials sponsored by Sun Yat-sen University, explained in plain language.
-
New combo attack on tough breast cancer
Disease control Recruiting nowThis study is testing different ways to combine radiation therapy with immunotherapy drugs to treat advanced triple-negative breast cancer (TNBC), a hard-to-treat form. It will enroll 60 patients who have not yet received chemotherapy for their advanced disease. The goal is to fi…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Radiation blitz tested to halt spread of kidney cancer
Disease control Recruiting nowThis study is for people whose kidney cancer has spread to only a few other places in the body. It tests if adding a very precise, high-dose radiation treatment to standard drug therapy works better than the drugs alone. The goal is to see if this combination can keep the cancer …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Robot surgeons battle video surgeons in major lung cancer trial
Disease control Recruiting nowThis large study aims to find out if robot-assisted surgery is as good as or better than standard video-assisted surgery for removing early-stage lung cancer. It will enroll over 1,100 patients with Stage I or II non-small cell lung cancer. Researchers will compare how long patie…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New hope for inoperable esophageal cancer: Triple-Threat treatment trial
Disease control Recruiting nowThis study is testing a new combination treatment for people with advanced esophageal cancer that cannot be removed by surgery. The treatment involves a targeted drug (surufatinib), immunotherapy (toripalimab), chemotherapy, and radiation. The goal is to see if this combination c…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Drug combo aims to make risky kidney cancer surgery safer
Disease control Recruiting nowThis study is testing whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted drug (lenvatinib) can shrink kidney tumors before surgery. The goal is to make a kidney-sparing operation possible and safer for 25 patients whose tumors are curr…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for Tough-to-Treat throat cancer patients
Disease control Recruiting nowThis study is testing a new drug called becotatug vedotin for people with advanced nasopharyngeal cancer (a type of throat cancer) who don't respond well to the standard first treatment of chemotherapy plus immunotherapy. The goal is to see if adding this new drug during radiatio…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Targeted therapy trial offers hope for advanced bladder cancer patients
Disease control Recruiting nowThis study is testing whether a targeted cancer drug called trastuzumab rezetecan works better alone or combined with an immunotherapy drug called adebrelimab for advanced bladder cancer that has spread. The trial will enroll 96 adults whose cancer has a specific marker called HE…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug duo aims to shrink tumors before liver cancer surgery
Disease control Recruiting nowThis study is testing a combination of two drugs, sintilimab and bevacizumab, given to patients before they have surgery to remove liver cancer. The goal is to see if this 'pre-surgery' treatment can help lower the high chance of the cancer returning after the operation. The tria…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Scientists hunt clues to make stem cell therapy work better for liver patients
Disease control Recruiting nowThis study looks back at past patients with severe liver failure caused by Hepatitis B who received stem cell (MSC) treatments. Researchers will analyze the medical records of 446 patients to understand why some people improved with the treatment while others did not. The goal is…
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New Two-Pronged attack on Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a two-part treatment for B-cell lymphoma that has come back or not responded to other therapies. First, doctors modify a patient's own immune cells (CAR-T cells) to attack the cancer. Then, they add an immunotherapy drug (sintilimab) for up to a year to help…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Gut bacteria boost tested in fight against aggressive breast cancer
Disease control Recruiting nowThis study is testing whether adding an oral probiotic supplement called Biolosion to standard chemotherapy before surgery is more effective for women with triple-negative breast cancer. Researchers want to see if the probiotic helps the body respond better to treatment, aiming f…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Four-Pronged attack on aggressive lung cancer enters human testing
Disease control Recruiting nowThis study is testing a new combination treatment for people with limited-stage small cell lung cancer, a fast-growing type of lung cancer. The treatment combines standard chemotherapy and radiation with two newer drugs: toripalimab (an immunotherapy) and surufatinib (a targeted …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New hope for advanced throat cancer: triple therapy trial seeks better control
Disease control Recruiting nowThis study is testing whether adding low-dose radiation and an immunotherapy drug to standard chemotherapy and radiation works better for advanced nasopharyngeal cancer. Researchers will compare the new combination approach against current standard treatment in 380 patients. The …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Sharper aim: new radiation technique seeks to zap lung cancer with fewer side effects
Disease control Recruiting nowThis study is testing if a more precise form of radiation therapy can control lung tumors while causing fewer breathing problems and other side effects. It will compare a new, adaptive radiation technique against the current standard in patients with early-stage lung cancer or a …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New hope for tough colon cancers: immune therapy before surgery
Disease control Recruiting nowThis study is testing whether giving immunotherapy drugs before surgery can help shrink tumors in people with advanced colorectal cancer that has specific genetic features. About 270 participants will receive either toripalimab alone or combined with celecoxib to see which approa…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
First-in-Human trial tests engineered immune cells against tough pancreatic cancer
Disease control Recruiting nowThis is an early-stage study to test the safety of a new treatment called IX001 TCR-T injection for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V mutation). The treatment involves collecting a patient's own immune cells, genetically modifyin…
Phase: PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New Triple-Threat attack on tough lung cancer
Disease control Recruiting nowThis study is testing a multi-step treatment plan for people with locally advanced non-small cell lung cancer that cannot be surgically removed. It combines chemotherapy, radiation, and two immunotherapy drugs designed to help the immune system fight cancer. The goal is to see if…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New hope for kids with Tough-to-Treat cancer
Disease control Recruiting nowThis study is testing whether adding a drug called apatinib to standard chemotherapy can help children and teenagers whose neuroblastoma has come back or hasn't responded to previous treatments. The trial will involve up to 125 participants aged 5-18 years old. Researchers want t…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New hope for Tough-to-Treat gut cancers
Disease control Recruiting nowThis study is testing a combination of three drugs (surufatinib, sintilimab, and capecitabine) for people with advanced small bowel or appendix cancer that has spread and worsened after at least one prior treatment. The main goals are to see if this combination is safe and if it …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New combo attack on throat cancer: trial tests three drug cocktails
Disease control Recruiting nowThis study aims to find the best initial chemotherapy combination to use with an immunotherapy drug (Toripalimab) for people with locally advanced nasopharyngeal cancer (a type of throat cancer). It will enroll 243 participants to compare three different drug combinations, all fo…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Heart watch during cancer fight could save lives
Disease control Recruiting nowThis study is testing whether closely monitoring and proactively managing heart health during intensive lung cancer treatment helps patients live longer and experience fewer serious heart problems. It will involve over 500 adults with advanced lung cancer who are receiving combin…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo aims to save kidneys in tough cancer cases
Disease control Recruiting nowThis study is testing if a combination of two drugs, pucotenlimab and vorolanib, can shrink kidney tumors before surgery. The goal is to make it possible for surgeons to remove the cancer while saving the healthy part of the kidney in patients where this is normally very difficul…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Brain tumor radiation gets a High-Tech, pinpoint upgrade
Disease control Recruiting nowThis study is testing a new, more precise way to deliver radiation to brain tumors that have spread from lung cancer. It uses real-time MRI scans to guide the radiation beam very accurately, allowing doctors to remove the standard safety margin around the tumor. The goal is to se…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Ice slush vs warm blood: which better protects kidneys during cancer surgery?
Disease control Recruiting nowThis study aims to find out if cooling the kidney with ice slush during robotic surgery to remove part of a cancerous kidney helps it recover better than keeping it warm. Researchers will randomly assign 310 patients to either the cold or warm technique and compare how well kidne…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for advanced breast cancer patients after standard treatments fail
Disease control Recruiting nowThis study tests whether personalized chemotherapy can better control advanced breast cancer that has progressed after standard treatments. Doctors will choose from several chemotherapy drugs based on each patient's specific situation and preferences. The trial aims to see if thi…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for Tough-to-Treat blood cancer? trial tests drug combo
Disease control Recruiting nowThis study is testing if adding a new drug called selinexor to a standard chemotherapy regimen (R-CHOP) works better for people with a specific, harder-to-treat type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 gene mutation. It will involve about 42 adults who have n…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo aims to stop liver Cancer's return
Disease control Recruiting nowThis study is testing a new treatment plan to stop liver cancer from coming back after surgery. Patients with high-risk liver cancer will receive a combination of targeted chemotherapy and an immunotherapy drug before their operation, followed by more immunotherapy after surgery.…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New two-drug combo aims to control rare lymphoma
Disease control Recruiting nowThis study is testing whether combining two existing drugs—zanubrutinib and rituximab—works better as a first treatment for MALT lymphoma, a type of slow-growing cancer that often starts in the stomach or other organs. Researchers will give the drug combination to 42 newly diagno…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New immunotherapy tested for Tough-to-Treat sarcomas
Disease control Recruiting nowThis study is testing an investigational immunotherapy drug called QL1706 for people with advanced bone and soft tissue sarcomas that cannot be surgically removed. The main goal is to see if the drug can control tumor growth for at least 12 weeks and to monitor its safety. About …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Four-Drug attack on Tough-to-Treat colon cancer
Disease control Recruiting nowThis study is testing a new combination of four drugs for adults with advanced colorectal cancer that has a specific genetic change called BRAF V600E. The goal is to see if this combination is safe and more effective than past treatments for this hard-to-treat cancer. About 20 pa…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Scientists test freezing & pill combo to fight spreading prostate cancer
Disease control Recruiting nowThis study is testing if a new combination of treatments works better than the current standard for men whose prostate cancer has already spread. It adds a procedure to freeze the prostate and a low-dose chemotherapy pill to the usual hormone-blocking drugs. Researchers want to s…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Smarter radiation aims to spare patients harsh side effects
Disease control Recruiting nowThis study is testing a more targeted approach to radiation therapy for nasopharyngeal cancer. It aims to see if focusing radiation only on specific areas of the neck, based on detailed scans, can reduce side effects like thyroid problems and swallowing issues while keeping cance…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Cancer trial questions need for immediate radiation
Disease control Recruiting nowThis study is for people with advanced nasopharyngeal cancer that has spread. It compares two approaches after initial drug therapy: getting radiation to the head and neck area right away versus waiting and only using radiation if the cancer comes back there. The main goal is to …
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for liver cancer patients who run out of options
Disease control Recruiting nowThis study is testing a new combination of two drugs, dalpiciclib and camrelizumab, for people with advanced liver cancer that cannot be removed by surgery. It is specifically for patients whose cancer has continued to grow despite receiving a type of treatment called immunothera…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New cancer trial tests if boosting immune system beats standard chemo
Disease control Recruiting nowThis study compares two treatment approaches for people with high-risk nasopharyngeal cancer that has spread locally. One approach adds immunotherapy drugs to standard chemotherapy and radiation, while the other uses standard chemotherapy alone for maintenance. The goal is to see…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Cancer trial aims to cut harsh radiation, spare Patients' side effects
Disease control Recruiting nowThis study is for people with advanced head and neck cancer who have already had surgery and a strong response to drug treatments. Researchers want to see if they can safely give less radiation therapy to the neck after surgery. The goal is to see if this lower dose still control…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
New hope for liver cancer patients when first treatment fails
Disease control Recruiting nowThis study is testing a new combination of drugs for patients with advanced liver cancer whose initial immunotherapy treatment has stopped working. It aims to see if adding a specific chemotherapy regimen to the original drugs can better control the cancer and extend life. The tr…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Could less radiation be just as good for throat cancer?
Disease control Recruiting nowThis study is testing if using a lower dose of radiation to treat certain areas around a throat cancer tumor is just as effective at controlling the cancer as the standard higher dose. It aims to see if the lower dose can provide the same survival benefits while causing fewer sid…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for advanced colon cancer patients in clinical trial
Disease control Recruiting nowThis study compares two different drug combinations for people with advanced colorectal cancer that has spread and cannot be surgically removed. Researchers want to see if adding a newer immunotherapy drug (envafolimab) to standard chemotherapy and targeted therapy helps control …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Timing test: does radiation after drugs help beat back returning cancer?
Disease control Recruiting nowThis study is for people whose nasopharyngeal cancer has returned after initial treatment. It tests whether adding radiation therapy immediately after a standard drug combination (immunotherapy plus chemotherapy) is better than waiting to see if it's needed later. The goal is to …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Faster radiation schedule tested in battle against tough esophageal cancer
Disease control Recruiting nowThis study is for people with advanced esophageal cancer that cannot be removed by surgery. It aims to see if a shorter, more intense course of radiation combined with chemotherapy and immunotherapy works better and is as safe as the standard, longer radiation schedule. All parti…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
First human test of new cancer drug begins
Disease control Recruiting nowThis is a very early study to check the safety and initial signs of effectiveness of a new drug called WTX212A. It will be given to 12 adults with advanced solid tumors, either by itself or combined with radiation therapy. The main goals are to see if the treatment is safe and ho…
Phase: PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New Three-Drug attack on rare melanoma before surgery
Disease control Recruiting nowThis study is testing whether giving a combination of three drugs before surgery can shrink tumors in patients with resectable mucosal melanoma, a rare and aggressive cancer. Thirty-two participants will receive the drug combination for about nine weeks, followed by surgery to re…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for Tough-to-Treat blood cancer patients
Disease control Recruiting nowThis study is testing whether combining a new drug called golidocitinib with one of two other medications is safe and effective for people whose peripheral T-cell lymphoma has returned or hasn't responded to previous treatments. The trial will involve about 101 adults at multiple…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for kids with tough liver cancer: Triple-Threat therapy trial opens
Disease control Recruiting nowThis study is testing a new combination of three drugs—an immunotherapy, a targeted therapy, and a chemotherapy—for children and teenagers with advanced hepatoblastoma, a type of liver cancer, that has come back or hasn't responded to standard treatments. The goal is to see if th…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Three-Drug attack on tough Head/Neck cancer shows promise
Disease control Recruiting nowThis study is testing a new combination of three immunotherapy drugs for people with advanced nasopharyngeal carcinoma (a type of head and neck cancer) that has come back or spread after their first treatment stopped working. The goal is to see if this three-drug approach is more…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Quick lab test during surgery could spare rectal cancer patients major operation
Disease control Recruiting nowThis study is testing a new surgical strategy for rectal cancer patients who have responded well to initial radiation treatment. During a minor surgery to remove the tumor, doctors will immediately analyze the tissue. If the analysis shows very little cancer remains, the patient …
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Blood test determines cancer treatment: less chemo for some, more for others
Disease control Recruiting nowThis large Phase 3 trial is testing a personalized treatment strategy for advanced nasopharyngeal cancer. After initial chemo-immunotherapy, patients are split into two groups based on a blood test for EBV-DNA. Low-risk patients receive less intensive treatment (radiation only) t…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
Cancer trial aims to cut radiation side effects without losing effectiveness
Disease control Recruiting nowThis study is testing whether a lower dose of radiation therapy works as well as the standard dose for certain patients with stage III nasopharyngeal cancer (a type of head and neck cancer). It will enroll about 593 patients in China who respond well to initial chemotherapy and i…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 11, 2026 14:52 UTC
-
Breakthrough trial aims to save more kids from rare liver cancer
Disease control Recruiting nowThis study is testing a new chemotherapy plan for children and teenagers with a rare liver cancer called hepatoblastoma. Researchers want to find the best drug combination to improve survival, especially for high-risk cases where current treatments often fail. They will also test…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Mar 02, 2026 15:26 UTC
-
New combo therapy trial aims to shrink tough liver tumors
Disease control Recruiting nowThis study tests whether adding two localized liver treatments to an approved drug combination can better shrink advanced liver cancer. It will involve about 55 adults with liver cancer that cannot be surgically removed. The main goal is to see how many patients' tumors respond t…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Feb 02, 2026 05:28 UTC
-
AI hunts for liver cancer before it strikes
Diagnosis Recruiting nowThis study aims to use artificial intelligence (AI) to analyze health data and better predict which people with hepatitis B and liver cirrhosis are at highest risk of developing liver cancer. It will enroll 6,000 high-risk participants to create a more precise follow-up and monit…
Sponsor: Sun Yat-sen University • Aim: Diagnosis
Last updated Mar 25, 2026 14:07 UTC
-
New breath of hope: inhaled drug aims to protect kids' airways during surgery
Prevention Recruiting nowThis study is testing whether inhaling a medication called penehyclidine before surgery can prevent breathing problems in children who are at higher risk. It involves 204 children aged 3 to 7 who are having eye surgery and have risk factors like recent colds, wheezing, or family …
Phase: PHASE4 • Sponsor: Sun Yat-sen University • Aim: Prevention
Last updated Mar 31, 2026 12:11 UTC
-
Ancient herbs tested to fight agonizing side effect of cancer treatment
Symptom relief Recruiting nowThis study is testing if adding a traditional Chinese herbal liquid called Houyanqing to standard care works better than standard care alone at preventing and reducing severe mouth sores in people receiving radiation therapy for nasopharyngeal cancer. It will involve 244 patients…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Mar 30, 2026 14:30 UTC
-
Herbal hope for cancer fatigue? trial tests capsule for Post-Chemo recovery
Symptom relief Recruiting nowThis study is testing whether a traditional Chinese medicine capsule called Xinlikang can help reduce severe fatigue and improve immune system function in people with diffuse large B-cell lymphoma who have finished their main chemotherapy. Researchers will compare the capsule to …
Phase: PHASE2, PHASE3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Mar 30, 2026 14:29 UTC
-
Heart valve study aims to predict patient outcomes
Knowledge-focused Recruiting nowThis study aims to better understand what factors put patients with a significant leak in their mitral heart valve at higher risk of death or hospitalization for heart failure. Researchers will follow 2,000 adult patients with this condition over time, collecting detailed heart u…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Scientists hunt for hidden clues in blood to predict heart valve problems
Knowledge-focused Recruiting nowThis study aims to understand heart valve disease better by looking for new chemical markers in the blood. Researchers will follow 4,000 adult patients with valve disease over time, tracking their health outcomes. The goal is to find connections between these blood markers and ho…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:29 UTC
-
Massive heart study tracks 30,000 patients to unlock survival secrets
Knowledge-focused Recruiting nowThis study aims to understand what factors influence survival and heart-related deaths in people with coronary artery disease. Researchers will follow 30,000 patients with various forms of heart artery disease over time. The goal is to identify which risk factors are most strongl…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:38 UTC
-
AI tutor put to the test in medical school
Knowledge-focused Recruiting nowThis study is testing whether a custom AI teaching assistant helps medical and nursing graduate students learn machine learning better than traditional teaching. About 56 students will use the AI tool for tutoring, research help, and coding guidance during their course. Researche…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC